Familial Hypercholesterolaemia Patients with LDLR Mutation Among Asian Population in Southeast Asian Countries: Systematic Review

(Nur Syahirah Shahuri, Noor Alicezah Mohd Kasim, Hapizah Md Nawawi, Yung-An Chua, Alyaa Al-Khateeb and Siti Hamimah Sheikh Abdul Kadir)

---

Abstract

Familial hypercholesterolaemia (FH) is a genetic disorder associated with premature cardiovascular diseases; however, the majority of patients remain undertreated. This systematic review aimed to determine the prevalence of FH patients with low-density lipoprotein receptor (LDLR) gene pathogenic variants (PV) among the Asian population in Southeast Asian countries. Our search yielded 1,120 citations, with 28 deemed possibly suitable based on title and abstract screening. However, only six studies that utilised the Dutch Lipid Clinic Network (DLCN) or Simon Broome (SB) criteria were eligible to be included. These studies provided prevalence figures for clinically diagnosed FH patients, with a total of 17.1% (n=1,005/5,874); this rate was represented by three Malaysian studies, which estimated that 36–76% of clinically diagnosed FH patients had LDLR PV. Most patients reported having pre-existing cardiovascular disease, a family history of premature coronary artery disease and tendon xanthomata. This study found that the prevalence of LDLR PV among genetically confirmed FH patients in Southeast Asia is 20.5% (n=286/5,874). Genetically confirmed FH patients are at a higher risk of developing premature coronary artery disease, requiring more aggressive lipid-lowering treatment. Therefore, identifying LDLR PV among the population is essential for early FH diagnosis and treatment.
KEYWORDS
Arterial disease, autosomal dominant, LDL receptor, LDLR prevalence, pathogenic variants, premature CAD, Undertreated

PDF

References

Al-Khateeb, A., Zahri, M.K., Mohamed, M.S., Sasongko, T.H., Ibrahim, S., Yusof, Z. and Zilfalil, B.A. (2011). Analysis of sequence variations in low-density lipoprotein receptor gene among Malaysian patients with familial hypercholesterolemia. BMC Medical Genetics, 12(n/a), 1–11. DOI: 10.1186/1471-2350-12-40
Beheshti, S.O., Madsen, C.M., Varbo, A. and Nordestgaard, B.G. (2020). Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. Journal of the American College of Cardiology, 75(20), 2553–66. DOI: 10.1016/j.jacc.2020.03.057
Birnbaum, R.A., Horton, B.H., Gidding, S.S., Brenman, L.M., Macapinlac, B.A. and Avins, A.L. (2021). Closing the gap: identification and management of familial hypercholesterolemia in an integrated healthcare delivery system. Journal of Clinical Lipidology, 15(2), 347–57. DOI: 10.1016/j.jacl.2021.01.008
Bouhairie, V.E. and Goldberg, A.C. (2015). Familial hypercholesterolemia. Cardiology Clinics, 33(2), 169–79. DOI: 10.1016/j.ccl.2015.01.001
Brown, M.S. and Goldstein, J.L. (1974a). Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science, 185(4145), 61–3. DOI: 10.1126/science.185.4145.61
Brown, M.S. and Goldstein, J.L. (1974b). Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proceedings of the National Academy of Sciences, 71(3), 788–92. DOI: 10.1073/pnas.71.3.788
Cho, S.M.J., Lee, H.J., Shim, J.S., Song, B.M. and Kim, H.C. (2020). Associations between age and dyslipidemia are differed by education level: The Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) cohort. Lipids in Health and Disease, 19(n/a), 1–12. DOI: 10.1186/s12944-020-1189-y
Chua, Y.A., Razman, A.Z., Ramli, A.S., Kasim, N.A.M. and Nawawi, H. (2021). Familial hypercholesterolaemia in the Malaysian community: prevalence, under-detection and under-treatment. Journal of Atherosclerosis and Thrombosis, 28(10), 1095–107. DOI: 10.5551/jat.57026
Cuchel, M., Bruckert, E., Ginsberg, H.N., Raal, F.J., Santos, R.D., Hegele, R.A. and Wiklund, O. (2014). Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal, 35(32), 2146–57. DOI: 10.1093/eurheartj/ehu274
EAS Familial Hypercholesterolaemia Studies Collaboration. (2018). Overview of the current status of familial hypercholesterolaemia care in over 60 countries-the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 277(n/a), 234–55. DOI: 10.1016/j.atherosclerosis.2018.08.051
Futema, M., Taylor-Beadling, A., Williams, M. and Humphries, S.E. (2021). Genetic testing for familial hypercholesterolemia—past, present, and future. Journal of Lipid Research, 62(n/a), n/a. DOI: 10.1016/J.JLR.2021.100139
Garcia, M., Mulvagh, S.L., Bairey Merz, C.N., Buring, J.E. and Manson, J.E. (2016). Cardiovascular disease in women: Clinical perspectives. Circulation Research, 118(8), 1273–93. DOI: 10.1161/CIRCRESAHA.116.307547
Goldstein, J.L. and Brown, M.S. (1973). Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proceedings of the National Academy of Sciences, 70(10), 2804–8. DOI: 10.1073/pnas.70.10.2804
Goldstein, J.L. and Brown, M.S. (1974). Binding and degradation of low-density lipoproteins by cultured human fibroblasts: comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. Journal of Biological Chemistry, 249(16), 5153–62. DOI: 10.1016/s0021-9258(19)42341-7
Hevonoja, T., Pentikäinen, M.O., Hyvönen, M.T., Kovanen, P.T. and Ala-Korpela, M. (2000). Structure of low-density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1488(3), 189–210. DOI: 10.1016/s1388-1981(00)00123-2
Hu, P., Dharmayat, K.I., Stevens, C.A., Sharabiani, M.T., Jones, R.S., Watts, G.F. and Vallejo-Vaz, A.J. (2020). Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: A systematic review and meta-analysis. Circulation, 141(22), 1742–59. DOI: 10.1161/CIRCULATIONAHA.119.044795
Iacocca, M.A., Chora, J.R., Carrié, A., Freiberger, T., Leigh, S.E., Defesche, J.C. and ClinGen FH Variant Curation Expert Panel. (2018). ClinVar database of global familial hypercholesterolemia‐associated DNA variants. Human Mutation, 39(11), 1631–1640. DOI: 10.1002/humu.23634
Kalra, S., Chen, Z., Deerochanawong, C., Shyu, K.G., San Tan, R., Tomlinson, B. and Yeh, H.I. (2021). Familial hypercholesterolemia in Asia Pacific: a review of epidemiology, diagnosis, and management in the region. Journal of Atherosclerosis and Thrombosis, 28(5), 417–34. DOI: 10.5551/jat.56762
Khoo, K.L., Van Acker, P., Defesche, J.C., Tan, H., Van de Kerkhof, L., Heijnen‐van Eijk, S. and Deslypere, J.P. (2000). Low‐density lipoprotein receptor gene mutations in a Southeast Asian population with familial hypercholesterolemia. Clinical Genetics, 58(2), 98–105. DOI: 10.1034/j.1399-0004.2000.580202.x
Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis, J.P. and Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine, 151(4), W-65. DOI: 10.1371/journal.pmed.1000100
Lye, S.H., Chahil, J.K., Bagali, P., Alex, L., Vadivelu, J., Ahmad, W.A.W. and Mohamed, R. (2013). Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia. PloS One, 8(4), e60729. DOI: 10.1371/journal.pone.0060729
Marusic, T., Sustar, U., Sadiq, F., Kotori, V., Mlinaric, M., Kovac, J. and Groselj, U. (2020). Genetic and clinical characteristics of patients with homozygous and compound heterozygous familial hypercholesterolemia from three different populations: Case series. Frontiers in Genetics, 11(n/a), 572176. DOI: 10.3389/fgene.2020.572176
McGowan, M.P., Hosseini Dehkordi, S.H., Moriarty, P.M. and Duell, P.B. (2019). Diagnosis and treatment of heterozygous familial hypercholesterolemia. Journal of the American Heart Association, 8(24), e013225. DOI: 10.1161/JAHA.119.013225
Medeiros, A.M. and Bourbon, M. (2023). Genetic testing in familial hypercholesterolemia: is it for everyone?. Current Atherosclerosis Reports, 25(4), 127–32. DOI: 10.1007/s11883-023-01091-5
Mickiewicz, A., Futema, M., Ćwiklinska, A., Kuchta, A., Jankowski, M., Kaszubowski, M. and Gruchała, M. (2020). Higher Responsiveness to Rosuvastatin in Polygenic versus Monogenic Hypercholesterolemia: A Propensity Score Analysis. Life, 10(5), 73. DOI: 10.3390/life10050073
Migliara, G., Baccolini, V., Rosso, A., D’Andrea, E., Massimi, A., Villari, P. and De Vito, C. (2017). Familial hypercholesterolemia: a systematic review of guidelines on genetic testing and patient management. Frontiers in Public Health, 5(n/a), 252. DOI: 10.3389/fpubh.2017.00252
Munn, Z., Moola, S., Lisy, K., Riitano, D. and Tufanaru, C. (2015). Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. JBI Evidence Implementation, 13(3), 147–53. DOI: 10.1097/XEB.0000000000000054
Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., Ginsberg, H.N., Masana, L., Descamps, O.S. and European Atherosclerosis Society Consensus Panel. (2013). Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European Heart Journal, 34(45), 3478–90. DOI: n10.1093/eurheartj/eht273
Packard, C., Chapman, M.J., Sibartie, M., Laufs, U. and Masana, L. (2021). Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart, 107(17), 1369–75. 
Pek, S.L.T., Dissanayake, S., Fong, J.C.W., Lin, M.X., Chan, E.Z.L., Justin, I. and Tavintharan, S. (2018). Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: single center study. Atherosclerosis, 269(n/a), 106–16. DOI: 10.1016/j.atherosclerosis.2017.12.028
Punzalan, F.E.R., Sy, R.G., Santos, R.S., Cutiongco, E.M., Gosiengfiao, S., Fadriguilan, E. and Laurie, A. (2005). Low Density Lipoprotein− Receptor (LDL-R) Gene Mutations among Filipinos with Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 12(5), 276–83. DOI: 10.5551/jat.12.276
Qin, D. (2019). Next-generation sequencing and its clinical application. Cancer Biology and Medicine, 16(1), 4. DOI: 10.20892/j.issn.2095-3941.2018.0055
Rallidis, L.S., Iordanidis, D. and Iliodromitis, E. (2020). The value of physical signs in identifying patients with familial hypercholesterolemia in the era of genetic testing. Journal of Cardiology, 76(6), 568–72. DOI: 10.1016/j.jjcc.2020.07.005
Razman, A.Z., Chua, Y.A., Mohd Kasim, N.A., Al-Khateeb, A., Sheikh Abdul Kadir, S.H., Jusoh, S.A. and Nawawi, H. (2022). Genetic spectrum of familial hypercholesterolaemia in the Malaysian community: Identification of pathogenic gene variants using targeted next-generation sequencing. International Journal of Molecular Sciences, 23(23), 14971. DOI: 10.3390/ijms232314971
Sharifi, M., Futema, M., Nair, D. and Humphries, S.E. (2019). Polygenic hypercholesterolemia and cardiovascular disease risk. Current Cardiology Reports, 21(n/a), 1–6. DOI: 10.1007/s11886-019-1130-z
Tada, H., Okada, H., Nomura, A., Usui, S., Sakata, K., Nohara, A. and Kawashiri, M.A. (2021). Clinical Diagnostic Criteria of Familial Hypercholesterolemia- A Comparison of the Japan Atherosclerosis Society and Dutch Lipid Clinic Network Criteria. Circulation Journal, 85(6), 891–7. DOI: 10.1253/circj.CJ-20-0901
Tanaka, N., Teramoto, T. and Yokoyama, S. (2019). Application of the Japanese guidelines for the diagnosis of familial hypercholesterolemia in general practice: It is to be validated in international harmonization. Journal of Atherosclerosis and Thrombosis, 26(1), 93–8. DOI: 10.5551/jat.46979
Trapani, L. and Pallottini, V. (2010). Age‐related hypercholesterolemia and HMG‐CoA reductase dysregulation: Sex does matter (a gender perspective). Current Gerontology and Geriatrics Research, 2010(1), 420139. DOI: 10.1155/2010/420139
Vrablik, M., Tichý, L., Freiberger, T., Blaha, V., Satny, M. and Hubacek, J.A. (2020). Genetics of familial hypercholesterolemia: new insights. Frontiers in Genetics, 11(n/a), 574474. DOI: 10.3389/fgene.2020.574474
Wald, D.S. and Wald, N.J. (2019). Integration of child–parent screening and cascade testing for familial hypercholesterolaemia. Journal of Medical Screening, 26(2), 71–5. DOI: 10.1177/0969141318796856
Wang, Y., Li, Y., Liu, X., Tu, R., Zhang, H., Qian, X. and Wang, C. (2019). The prevalence and related factors of familial hypercholesterolemia in rural population of China using Chinese modified Dutch Lipid Clinic Network definition. BMC Public Health, 19(n/a), 1–7. DOI: 10.1186/s12889-019-7212-4
Woodward, M. (2019). Cardiovascular disease and the female disadvantage. International Journal of Environmental Research and Public Health, 16(7), 1165. DOI: 10.3390/ijerph16071165
Zubielienė, K., Valterytė, G., Jonaitienė, N., Žaliaduonytė, D. and Zabiela, V. (2022). Familial hypercholesterolemia and its current diagnostics and treatment possibilities: a literature analysis. Medicina, 58(11), 1665. DOI: 10.3390/medicina58111665